BioSpace

Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

18 Dec 2025

Contributed by Lukas

In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, about...

Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets

17 Dec 2025

Contributed by Lukas

Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide. Results from...

Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment

11 Dec 2025

Contributed by Lukas

In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepa...

Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs

10 Dec 2025

Contributed by Lukas

Pfizer followed up its winning $10 billion bid forobesity startup Metsera by adding another molecule to its obesity cabinet, thisone from Chinese firm...

New Approach Methodologies: Redefining Animal Testing Alternatives

04 Dec 2025

Contributed by Lukas

Momentum is building behind New Approach Methodologies (NAMs) that offer stronger human relevance than traditional animal testing. The FDA issued on D...

Prasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs

03 Dec 2025

Contributed by Lukas

Vinay Prasad’s memo, leaked over the weekend, has sent vaccine makers’ stocks slipping and experts clamoring for more evidence to support the CBER...

Billions More in M&A, Another Bidding War and More FDA Drama

19 Nov 2025

Contributed by Lukas

Acquisitions have ticked up this month as all eyes were on Pfizer and Novo’s fight over Metsera. The past week saw that deal finalized with Pfizer a...

How Biotech Funding is Changing Executive Search and Hiring Processes

13 Nov 2025

Contributed by Lukas

A lean funding environment has changed how biotechs approach workforce organization and executive hiring. Searches are becoming more targeted and inte...

Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers

12 Nov 2025

Contributed by Lukas

One of biopharma’s most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but wi...

Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience

06 Nov 2025

Contributed by Lukas

This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our gu...

Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks

05 Nov 2025

Contributed by Lukas

Many of the top stories of 2025 are currently being written. We’re on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duk...

Innovation, Resilience, and the Future of Global Manufacturing

30 Oct 2025

Contributed by Lukas

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how China, historically focused on manufacturing, is increasing...

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More

29 Oct 2025

Contributed by Lukas

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. ...

How Supply Chain Turbulence is Reshaping Biotech Strategy

23 Oct 2025

Contributed by Lukas

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney how in light of economic uncertainty, small biotechs can turn to intern...

Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn

22 Oct 2025

Contributed by Lukas

Novo Nordisk dominated the news cycle this week, with more leadership changes as the Novo Foundation replaced the company’s board, which will now be...

Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma

21 Oct 2025

Contributed by Lukas

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospita...

Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing

16 Oct 2025

Contributed by Lukas

This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as t...

Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC

15 Oct 2025

Contributed by Lukas

Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and t...

Bonus: Q3 2025 Job Market Update

14 Oct 2025

Contributed by Lukas

In this discussion, BioSpace’s vice president of marketing ⁠⁠Chantal Dresner⁠⁠ and careers editor ⁠⁠Angela Gabriel⁠⁠ take a look at ...

Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa

08 Oct 2025

Contributed by Lukas

The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But...

Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems

02 Oct 2025

Contributed by Lukas

Clinical trials can present many challenges for patients–particularly injections.Oliver Eden, senior business unit director at Jabil, and Travis Web...

M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s

01 Oct 2025

Contributed by Lukas

Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year’s fifth larges...

FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More

24 Sep 2025

Contributed by Lukas

The FDA is working to reapprove GSK’s long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “devel...

What Do AI and Hammers Have in Common?

18 Sep 2025

Contributed by Lukas

In this episode, Lori Ellis and Colin Zick spend a little time further discussing some of the points brought up in the Bioprocessing Summit last month...

China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More

17 Sep 2025

Contributed by Lukas

A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. f...

Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More

10 Sep 2025

Contributed by Lukas

The Make America Healthy Again Commission released itssecond report Tuesday, recommending, among other efforts, an investigation into a possible link ...

The 'Research Safety Net' Saving Scientists from Funding Crisis

04 Sep 2025

Contributed by Lukas

In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the curre...

CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More

03 Sep 2025

Contributed by Lukas

We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex’s new pact with Enlaza fo...

Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change

27 Aug 2025

Contributed by Lukas

Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to h...

Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations

26 Aug 2025

Contributed by Lukas

Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This mont...

Why AI Won't Save the 90% of Clinical Trials That Still Fail

21 Aug 2025

Contributed by Lukas

While AI represents a significant advancement in efficiency for early-stage drug discovery, it won't dramatically change the 90% clinical trial fa...

MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum

20 Aug 2025

Contributed by Lukas

Three months after taking heat over an error-riddled first report, Health Secretary Robert F. Kennedy’s Make America Healthy Again Commission was du...

The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know

14 Aug 2025

Contributed by Lukas

In this Denatured discussion, the conversation revolves around unpacking the patent policy changes that could make or break biotech companies. Guests ...

Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues

13 Aug 2025

Contributed by Lukas

Vinay Prasad is back at the FDA as chief of the FDA’s Center for Biologics Evaluation and Research. Prasad’s return—which hit the news wires Sat...

From Chat Bots to World Order: The Race for the 21st Century's Operating System

07 Aug 2025

Contributed by Lukas

In this thought-provoking episode, Cresset Group’s CSO, Mark Mackey, and VP of AI, Mutlu Dogruel, dissect the emerging geopolitical battle for AI su...

FDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More

06 Aug 2025

Contributed by Lukas

Center for Drug Evaluation and Research Head George Tidmarsh will oversee the Center for Biologics Evaluation and Research on an acting basis after Vi...

We Don't Own Patient Data–We're Just Babysitting It

31 Jul 2025

Contributed by Lukas

While AI excels at repetitive tasks like triaging medical information calls, document retrieval, and adverse event detection, the industry must addres...

Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings

30 Jul 2025

Contributed by Lukas

The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company’s Duchenne muscular dystrophy gene therap...

Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions

23 Jul 2025

Contributed by Lukas

Just a few weeks ago, it seemed like Sarepta had weathered a spate of bad news, after two patients died from liver injuries from its Duchenne muscular...

Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines

22 Jul 2025

Contributed by Lukas

This episode continues the discussion regarding the rapid evolution of mRNA technologies since COVID-19. Guests discuss the improvements that have occ...

AI Is Taking Over Drug Safety Monitoring–But There's One Thing It Can't Replace

17 Jul 2025

Contributed by Lukas

This episode focuses on how AI is transforming pharmacovigilance (PV) on a global scale, particularly focusing on the evolving role of local qualified...

FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease

16 Jul 2025

Contributed by Lukas

Up to 3,500 FDA staffers received their final walking papers Monday after the U.S. Supreme Court found last week that the government is “likely to s...

Bonus Episode: Q2 2025 Job Market Update

15 Jul 2025

Contributed by Lukas

In this discussion, BioSpace’s vice president of marketing ⁠⁠Chantal Dresner⁠⁠ and careers editor ⁠⁠Angela Gabriel⁠⁠ take a look...

The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines

10 Jul 2025

Contributed by Lukas

This discussion focuses on how mRNA and self-replicating RNA (srRNA) technologies are expanding far beyond COVID vaccines into revolutionary therapeut...

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

09 Jul 2025

Contributed by Lukas

While most of the U.S. was celebrating the 4th of July holiday, President Donald Trump was busy signing the One Big, Beautiful Bill into law. This wid...

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

02 Jul 2025

Contributed by Lukas

The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be ...

Understanding the FDA's AI Guidance in Pharmacovigilance

01 Jul 2025

Contributed by Lukas

In this episode of Denatured, Archana Hegde from IQVIA discusses the practical challenges faced by pharmacovigilance (PV) professionals as they naviga...

FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap

25 Jun 2025

Contributed by Lukas

Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce Tuesday, where Democrats confronted the health secretary on hot...

Navigating Funding Freezes and AI Frontiers

19 Jun 2025

Contributed by Lukas

Lori Ellis, head of insights at BioSpace, discusses some of the recent events and topics that are buzzing around BIO and DIA in 2025 with Rich Daly, C...

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

18 Jun 2025

Contributed by Lukas

This week, BioSpace is at 50% power as Heather McKenzie and Jef Akst are off attending this year’s BIO Conference in Boston. The half-team discusses...

RFK Axes CDC Vaccine Advisors ; Metsera’s Weight Loss Win; FDA Supports CGT

11 Jun 2025

Contributed by Lukas

This week the BioSpace team was sent into an after-hours scramble by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had fired...

AI's Role in Decoding the FDA's New Regulatory Communications

05 Jun 2025

Contributed by Lukas

In a dynamic regulatory environment, IQVIA’s Michelle Gyzen suggests that AI may be the best and only way to keep with changes that are happening da...

M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama

04 Jun 2025

Contributed by Lukas

The words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key thera...

COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN

28 May 2025

Contributed by Lukas

The name of the biopharma game this season is vaccines—and RFK Jr. wasted no time returning from Memorial Day Weekend before making news on this fro...

How Target Product Profiles Guide the Industry Through Uncertain Times

22 May 2025

Contributed by Lukas

Lori Ellis, head of insights and Ian Fisher, head of development of analytics at IQVIA, discusses the critical importance of Target Product Profiles (...

Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan

21 May 2025

Contributed by Lukas

Pfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after i...

Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter

14 May 2025

Contributed by Lukas

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of ...

Eroding Immunity: Vaccine Hesitancy and Cynicism

08 May 2025

Contributed by Lukas

Paul Offit, MD, Director of the Vaccine Education Center at the Children's Hospital of Philadelphia and the Maurice R. Hilleman Professor of Vaccinolo...

Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review

07 May 2025

Contributed by Lukas

In his effort to onshore manufacturing, President Donald Trump issued an executive order on Monday afternoon ordering the FDA to ease permitting proce...

Tariffs Continue to Dominate Q1 Earnings, AACR Excites Cancer Space, CEO Pay Gaps, More

30 Apr 2025

Contributed by Lukas

Policy issues—particularly tariffs—loom large as Q1 2025 earnings season rolls on, with Pfizer , Novartis, AstraZeneca and many more all reporting...

Economic Challenges, Strategic Investments: Reshaping the Women's Health Landscape

24 Apr 2025

Contributed by Lukas

This discussion features BioSpace's head of insights Lori Ellis, Kearney partner Martin Hadosi, and Melissa Laitner, director of strategic initiat...

Makary’s First Interview, US Manufacturing Push and Lilly vs. Novo in Obesity Pill Race

23 Apr 2025

Contributed by Lukas

While much of the country was off celebrating Easter and Passover this weekend, the FDA—and its new leader Marty Makary—were busy making news. Mak...

Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed

16 Apr 2025

Contributed by Lukas

It’s all about tariffs again this week. No sooner had Donald Trump announced that “major” tariffs on the pharmaceutical industry would be coming...

Bonus: Q1 2025 Job Market Update

15 Apr 2025

Contributed by Lukas

In this bonus episode, BioSpace’s vice president of marketing ⁠Chantal Dresner⁠ and careers editor ⁠Angela Gabriel⁠ take a look at job...

Breaking Down Barriers: The Nuanced Approach to Women's Representation in Medical Research

10 Apr 2025

Contributed by Lukas

This discussion features BioSpace's head of insights Lori Ellis, Kearney partner Martin Hadosi, and Melissa Laitner, director of strategic initiat...

Tariff-Triggered Recession Fears, Fallout From HHS Cuts, Knockoff GLP-1s and More

09 Apr 2025

Contributed by Lukas

Pushback against the Trump administration’s massive government cuts exploded this weekend across America—and biopharma is no exception. Taking a d...

FDA on Fire, Novo’s Mixed Bag of Semaglutide Cardio Data, Kisunla’s EU Miss, More

02 Apr 2025

Contributed by Lukas

Biopharma’s reaction to the forced resignation of venerable CBER director Peter Marks has been swift and furious, with former FDA Commissioner Rober...

Balancing Protection and Inclusion: The Evolution of Women in Clinical Trials

27 Mar 2025

Contributed by Lukas

Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives, National Academy of Medicine, join Lori Ellis, head of insig...

Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More

26 Mar 2025

Contributed by Lukas

President Donald Trump doubled down on tariff threats targeting pharma, saying additional levies on pharmaceuticals will come “at some point,” per...

Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio

19 Mar 2025

Contributed by Lukas

A patient with Duchenne muscular dystrophy taking Sarepta’s gene therapy Elevidys has died of acute liver failure, possibly related to a recent vira...

A Conversation With Mark McKenna, CEO of Mirador

18 Mar 2025

Contributed by Lukas

On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Mark McK...

“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health

13 Mar 2025

Contributed by Lukas

Miruna Sasu, CEO of COTA, has been labeled as a disrupter in the industry. In this episode, she discusses the challenges of stringent inclusion and ex...

COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More

12 Mar 2025

Contributed by Lukas

As we mark five years since the World Health Organization officially declared the COVID-19 pandemic, the BioSpace editorial team reflects on the healt...

Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More

05 Mar 2025

Contributed by Lukas

Donald Trump’s tariffs have headlined myriad news stories this week—including at BioSpace, where we reported Pfizer CEO Albert Bourla’s claim th...

A Conversation With Kevin Marks, CEO of Delphia

04 Mar 2025

Contributed by Lukas

On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Kevin ...

Money Meets Medicine: A Disruptor's Guide to Life Sciences Investment

27 Feb 2025

Contributed by Lukas

Miruna Sasu, CEO of COTA, has been labeled as a disrupter in the industry. In this discussion, she highlights the challenges of investing in the life ...

Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More

26 Feb 2025

Contributed by Lukas

There was a high point this week for employees riding the rollercoaster that is currently the FDA, as 300 recently fired employees are reportedly bein...

Examining Gene Therapies, Bispecific Antibodies and Other Novel Modalities

25 Feb 2025

Contributed by Lukas

At the 2025 National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to medicine—wil...

Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom

19 Feb 2025

Contributed by Lukas

President Trump has been on a staff cutting rampage since taking office, and this weekend, the hammer came down on an undisclosed number of FDA employ...

A Conversation With Dannielle Appelhans, CEO of COUR

18 Feb 2025

Contributed by Lukas

On the sidelines of this year’s J.P. Morgan Healthcare Conference in San Francisco, BioSpace Senior Editor Annalee Armstrong sat down with Dannielle...

Navigating Patient Journeys with Tom Whitehead

13 Feb 2025

Contributed by Lukas

BioSpace’s Head of Insights Lori Ellis and Tom Whitehead, co-founder of the Emily Whitehead Foundation discuss the challenges navigated by cancer p...

New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs

12 Feb 2025

Contributed by Lukas

We saw more action on the M&A front this week as Novartisbought back its blood thinner abelacimab and the rest of Anthos Therapeutics for up to $3...

RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market

05 Feb 2025

Contributed by Lukas

U.S. political maneuverings are keeping biopharma on its toes. Tuesday, Robert F. Kennedy, Jr. passed a major hurdle as the Senate Finance Committee v...

The Patient's Perspective with Tom Whitehead

30 Jan 2025

Contributed by Lukas

BioSpace's Head of Insights Lori Ellis and Tom Whitehead sit down and discuss cell and gene therapies from the perspectives of patients. What do c...

RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More

29 Jan 2025

Contributed by Lukas

In the week since Donald Trump took office, he’s caused quite the stir with healthcare-centered moves that include ordering the Department of Health...

Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM

22 Jan 2025

Contributed by Lukas

Donald Trump was sworn in as the 47th president of the United States on Monday, bringing with him a host of healthcare nominees and potential changes ...

Bonus: Q4 2024 Job Market Update

21 Jan 2025

Contributed by Lukas

In this bonus episode, BioSpace's vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at Q4 job market perfo...

A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025

16 Jan 2025

Contributed by Lukas

In this episode of Denatured, Dr. Peter Marks M.D., PhD. gives his thoughts on the future of cell and gene therapies. He speaks candidly about opportu...

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

15 Jan 2025

Contributed by Lukas

The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. John...

A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)

10 Jan 2025

Contributed by Lukas

TEASER: This episode is little sneak peak into upcoming podcasts as well as topics that will be discussed at the 2025 GenScript Biotech Global Forum o...

NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch

08 Jan 2025

Contributed by Lukas

Happy New Year! BioSpace released our NextGen: Class of 2025 this week, highlighting 25 biopharma startups to watch this year. The companies on this l...

Trials and Capital: Women’s Health and APAC's Healthcare Revolution

02 Jan 2025

Contributed by Lukas

This conversation focused on a few remaining topics discussed at length at Jefferies late last year, with the same topics anticipated to make an appea...

Analysis vs Beliefs, CEO Challenges, GLP-1 Investments

19 Dec 2024

Contributed by Lukas

2025 is set to change the industry. The new administration is poised to challenge many existing processes. The question is whether they will be based ...

Biopharma’s Manufacturing Push and Other 2024 Trends

18 Dec 2024

Contributed by Lukas

Note: BioSpace is taking a break for the holidays. The next episode of The Weekly will air Jan. 8, 2025. Happy New Year! Novo dominated headlines over...

Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More

11 Dec 2024

Contributed by Lukas

This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive adva...

Previous Investment Patterns Set to Repeat in 2025

05 Dec 2024

Contributed by Lukas

“Cautious optimism” is circling once again as the industry approaches 2025. However, many companies are treading water, barely holding on as the m...

Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More

04 Dec 2024

Contributed by Lukas

It’s officially holiday shopping season, and biopharma is getting into the spirit. Novartis expanded its presence in Huntington’s, paying up to $2...

BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More

27 Nov 2024

Contributed by Lukas

Biopharma had its collective deal-making hat on heading into the Thanksgiving holiday, with Roche buying Poseida for up to $1.5 billion, and Sarepta a...

51%: The Untapped Market

21 Nov 2024

Contributed by Lukas

Women represent 51% of the population; not investing is a poor investment strategy. Incorporating women into leadership positions, into board rooms, i...

RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More

20 Nov 2024

Contributed by Lukas

President-elect Donald Trump announced last week that he would nominate prominent anti-vaxxer Robert F. Kennedy Jr. to lead the HHS. While this news c...